{
  "links": "https://www.ycombinator.com/companies/oncobox",
  "name": "Oncobox",
  "headline": "Finding the right cancer drug for each patient.",
  "batch": "S17",
  "description": "Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%.\r\n\nHow does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs.\r\n\nOncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient.\r\n\nWe actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. \r\n\nOur team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.",
  "activity_status": "Active",
  "website": "http://oncobox.com",
  "founded_date": null,
  "team_size": 11.0,
  "location": "Walnut, CA",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:drug-discovery; industry:oncology",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown='[To main content](http://oncobox.com/<#t-main-content>)\\n[](http://oncobox.com/</login>)\\n[Diagnostics](http://oncobox.com/</#01>)\\n[Clinical effectiveness](http://oncobox.com/</#02>)\\n[Research](http://oncobox.com/</#03>)\\n[About](http://oncobox.com/</#04>)\\n[![](https://static.tildacdn.com/tild3536-3163-4837-a433-306336613135/oncobox_logo.svg)](http://oncobox.com/<#first>)\\n[![](https://static.tildacdn.com/tild6238-3435-4762-b232-356638643536/burger.svg)](http://oncobox.com/<#menuopen>)\\n![](https://static.tildacdn.com/tild3331-3865-4363-a163-323065326431/oncobox_logo_white.svg)\\n[Log in](http://oncobox.com/</login>)\\n[![](https://static.tildacdn.com/tild3366-3836-4138-b664-303963636466/Vector_1.svg)](http://oncobox.com/</login>)\\n![](https://static.tildacdn.com/tild6564-3731-4164-b934-366139383534/oncobox_logo_white.svg)\\n  * [Diagnostics](http://oncobox.com/</#01>)\\n  * [Clinical effectiveness](http://oncobox.com/</#02>)\\n  * [Research](http://oncobox.com/</#03>)\\n  * [About](http://oncobox.com/</#04>)\\n\\n\\n[](http://oncobox.com/</login>)Log in  \\n---  \\n![](https://static.tildacdn.com/tild3163-3739-4639-a265-313266373536/12.png)\\n[](http://oncobox.com/</login>)\\n![](https://static.tildacdn.com/tild6535-3630-4236-b761-613238653331/13-3.png)\\n![](https://static.tildacdn.com/tild3731-3565-4830-b838-656238633733/12.png)\\n![](https://static.tildacdn.com/tild3066-3437-4934-b363-653637336634/11.png)\\nEffective cancer therapybased on tumor deep molecular profiling\\n![](https://static.tildacdn.com/tild3564-3962-4465-a339-306137643963/2.svg)\\nEvery tumor is unique, and at Oncobox, we\\'ve pioneered a groundbreaking solution to ensure the treatment is as exceptional as each individual.Oncobox Dx considers all molecular nuances of a tumor and evaluates the effectiveness of 170 novel targeted and immunotherapy drugs, assisting the healthcare provider in crafting a highly effective treatment plan.Let\\'s elevate cancer care with unparalleled precision.\\n[Diagnostics](http://oncobox.com/<#01>)\\n[Clinical effectiveness](http://oncobox.com/<#02>)\\n[Research](http://oncobox.com/<#03>)\\n[About](http://oncobox.com/<#04>)\\n![](https://static.tildacdn.com/tild6434-6565-4837-a534-656434616538/oncobox_logo.svg)\\n[![](https://static.tildacdn.com/tild6238-3435-4762-b232-356638643536/burger.svg)](http://oncobox.com/<#menuopen>)\\n![](https://static.tildacdn.com/tild6336-6233-4132-b639-346638333639/logo_white.svg)\\n[Log in](http://oncobox.com/</login>)\\n[![](https://static.tildacdn.com/tild6663-3763-4539-a434-353337623134/Vector_1.svg)](http://oncobox.com/</login>)\\n[](http://oncobox.com/<#test>)\\n[Learn more](http://oncobox.com/<#test>)\\n[![](https://static.tildacdn.com/tild6663-3763-4539-a434-353337623134/Vector_1.svg)](http://oncobox.com/<#test>)\\n![](https://static.tildacdn.com/tild6462-6664-4638-a532-663938626663/11.png)\\n![](https://static.tildacdn.com/tild3665-3135-4439-a662-373161656438/Subtract.svg)\\n![](https://static.tildacdn.com/tild3639-3632-4361-a336-666430626233/13.svg)\\n![](https://static.tildacdn.com/tild3930-3162-4561-b435-643635633030/12.png)\\nYou can access Oncobox testing by consulting with an oncologist at one of our affiliated clinics. This process typically involves sending a tumor sample to our laboratory for comprehensive genomic profiling.\\n01\\nThe report provides a detailed list of molecular abnormalities, ranks the drugs accordingly, and includes outcomes from clinical trials. This information empowers the physician or medical board to devise the most effective treatment strategy.\\n03\\nThe testing includes analysis of changes in DNA and RNA obtained from a tumor sample. Oncobox predicts the efficacy of over 170 targeted and immunotherapeutic drugs and generates a personalized drug ranking tailored to the specific patient.\\n02\\n![](https://static.tildacdn.com/tild3238-6561-4035-b335-376136366130/scene_02_eng_676453.png)\\n![](https://static.tildacdn.com/tild3430-6565-4065-a461-316465396133/Group_1732.png)\\n![](https://static.tildacdn.com/tild3365-6462-4234-a239-316637646266/A4_paper_eng.png)\\nClinical efficacy ofOncobox Dx\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6539-3737-4833-a466-353932613566/757575.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n[![](https://static.tildacdn.com/tild6333-3464-4265-a336-323738343539/Frame_1536.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[Biomedicines](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6138-3764-4163-b561-643338613866/34.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n[![](https://static.tildacdn.com/tild3266-3261-4631-a264-373732356263/Frame_1535.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[Experimental Hematology & Oncology](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild3239-6433-4966-a239-626532636239/01010.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\novarian cancer\\nFemale, 40 years\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![](https://static.tildacdn.com/tild3762-3762-4132-a564-616366663561/verified-logo-2-2_2.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nOncobox analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient’s disease.\\n[![](https://static.tildacdn.com/tild3734-3836-4836-b033-636362326561/Frame_1537.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[CSH Molecular Case Studies](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6634-6263-4439-b234-613933323062/Frame_1526.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nlung cancer\\nMale, 48 years\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild3432-3534-4565-b930-373331626463/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3837-3264-4366-b732-376638333634/verified-logo-1_4.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nSurvival of our patient after developing resistance to ALK inhibitor was longer for 16 months than previously reported average survival for such cases.\\n[![](https://static.tildacdn.com/tild6132-3261-4630-b839-373865323636/Frame_1535.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[Frontiers in Oncology](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6539-3737-4833-a466-353932613566/757575.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n[![](https://static.tildacdn.com/tild6333-3464-4265-a336-323738343539/Frame_1536.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[Biomedicines](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6138-3764-4163-b561-643338613866/34.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n[![](https://static.tildacdn.com/tild3266-3261-4631-a264-373732356263/Frame_1535.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[Experimental Hematology & Oncology](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild3239-6433-4966-a239-626532636239/01010.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\novarian cancer\\nFemale, 40 years\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![](https://static.tildacdn.com/tild3762-3762-4132-a564-616366663561/verified-logo-2-2_2.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nOncobox analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient’s disease.\\n[![](https://static.tildacdn.com/tild3734-3836-4836-b033-636362326561/Frame_1537.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[CSH Molecular Case Studies](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6634-6263-4439-b234-613933323062/Frame_1526.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nlung cancer\\nMale, 48 years\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild3432-3534-4565-b930-373331626463/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3837-3264-4366-b732-376638333634/verified-logo-1_4.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nSurvival of our patient after developing resistance to ALK inhibitor was longer for 16 months than previously reported average survival for such cases.\\n[![](https://static.tildacdn.com/tild6132-3261-4630-b839-373865323636/Frame_1535.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[Frontiers in Oncology](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6539-3737-4833-a466-353932613566/757575.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n[![](https://static.tildacdn.com/tild6333-3464-4265-a336-323738343539/Frame_1536.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[Biomedicines](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n[![](https://static.tildacdn.com/tild6138-3764-4163-b561-643338613866/34.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n[![](https://static.tildacdn.com/tild3266-3261-4631-a264-373732356263/Frame_1535.svg)](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[Experimental Hematology & Oncology](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n[![](https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg)](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6633-3636-4666-b964-636538643439/arrow-left.svg)\\n![](https://static.tildacdn.com/tild6438-6238-4534-a531-316566306531/arrow-right.svg)\\n![](https://static.tildacdn.com/tild3564-3934-4434-a563-366139643561/Subtract.svg)\\n![](https://static.tildacdn.com/tild3766-3934-4639-b832-343533396135/Group_1788.svg)\\n![](https://static.tildacdn.com/tild6136-6636-4664-a265-326136616131/Group_1789.svg)\\n![](https://static.tildacdn.com/tild3566-3433-4232-a534-323962666261/Group_1792.svg)\\n![](https://static.tildacdn.com/tild3933-3034-4463-a431-373866616364/asco-logo-header-des.png)\\nThe effectiveness of Oncobox technology has been validated through both retrospective and prospective clinical studies. In these trials, hundreds of late-stage cancer patients received personalized recommendations for targeted drugs based on their individual DNA & RNA profiling and Oncobox ratings, demonstrating the clinical impact of our solution.\\n![](https://static.tildacdn.com/tild3135-3633-4639-a462-356662313865/header-8e0456ae95ea8.png)\\n![](https://static.tildacdn.com/tild6466-6338-4162-a233-393664616166/Group_1593.png)\\n![](https://static.tildacdn.com/tild3231-3236-4835-a432-623335336131/verified-logo-1_2.png)\\n![](https://static.tildacdn.com/tild3330-3933-4064-b936-653632323363/Seminars_in_Cancer_B.png)\\n[View articles](http://oncobox.com/</our_research>)\\n[![](https://static.tildacdn.com/tild3136-3836-4362-a531-356431396634/Vector_1.svg)](http://oncobox.com/<https:/oncobox.ru/our_research.html>)\\n![](https://static.tildacdn.com/tild3734-6430-4362-a361-343066353231/Subtract.svg)\\n![](https://static.tildacdn.com/tild3764-3362-4432-b331-346632626530/Subtract.svg)\\n![](https://static.tildacdn.com/tild6438-6565-4236-b137-653265613866/Subtract.svg)\\n![](https://static.tildacdn.com/tild3931-3364-4437-b162-613132343666/Subtract.svg)\\nOncobox Diagnostics\\n![](https://static.tildacdn.com/tild3166-3833-4433-b361-643439653332/box___flyer_eng.png)\\n![](https://static.tildacdn.com/tild6131-3135-4234-a463-386135396166/1_-_Group_1695.svg)\\n![](https://static.tildacdn.com/tild3135-3366-4130-b034-343766373732/2_-_Group_1696.svg)\\n![](https://static.tildacdn.com/tild6139-3637-4437-b237-346439616434/3_-_Group_1697.svg)\\n![](https://static.tildacdn.com/tild3639-3738-4438-b538-613963323937/4_-_Group_1698.svg)\\n![](https://static.tildacdn.com/tild3332-6630-4365-b263-633165373236/5_-_Group_1699.svg)\\n![](https://static.tildacdn.com/tild6562-6532-4664-b636-633639333963/6_-_Group_1700.svg)\\n[![](https://static.tildacdn.com/tild3231-3634-4537-a133-336236623039/Group_1594.svg)](http://oncobox.com/<https:/oncobox.ru/materials/oncobox_report.pdf>)\\n![](https://static.tildacdn.com/tild3835-6463-4664-a433-633830613036/Group_1648_5.svg)\\n![](https://static.tildacdn.com/tild3433-6266-4065-b539-666435366433/Group_1648_2.svg)\\n![](https://static.tildacdn.com/tild3336-3636-4439-a630-616131303330/Group_1648_3.svg)\\n![](https://static.tildacdn.com/tild3530-6363-4530-b963-383836643065/Group_1648_6.svg)\\n![](https://static.tildacdn.com/tild3434-3339-4362-b435-626537323466/Group_1648_4.svg)\\n[![](https://static.tildacdn.com/tild3964-6561-4834-b039-356634616462/Group_1793.svg)](http://oncobox.com/<#popuppdf3>)\\n[![](https://static.tildacdn.com/tild6331-6132-4739-b063-613566653439/Group_1701.svg)](http://oncobox.com/<#popuppdf3>)\\n![](https://static.tildacdn.com/tild3134-6137-4233-a563-323064313036/Group_1648_1.svg)\\n![](https://static.tildacdn.com/tild3561-6231-4162-a363-386661353637/2.png)\\n![](https://static.tildacdn.com/tild3530-6637-4965-b934-393639633061/Subtract.png)\\nI consent to the processing of my personal data.\\nSubmit\\n[{\"lid\":\"1531306540094\",\"ls\":\"10\",\"loff\":\"\",\"li_type\":\"nm\",\"li_name\":\"name\",\"li_ph\":\"Name\",\"li_req\":\"y\",\"li_nm\":\"name\"},{\"lid\":\"1680696408713\",\"ls\":\"20\",\"loff\":\"\",\"li_type\":\"ph\",\"li_ph\":\"\\\\u0422\\\\u0435\\\\u043b\\\\u0435\\\\u0444\\\\u043e\\\\u043d\",\"li_masktype\":\"a\",\"li_nm\":\"Phone\"},{\"lid\":\"1531306243545\",\"ls\":\"30\",\"loff\":\"\",\"li_type\":\"em\",\"li_name\":\"examplemail.com\",\"li_ph\":\"Email\",\"li_req\":\"y\",\"li_nm\":\"examplemail.com\"},{\"lid\":\"1688043139550\",\"ls\":\"40\",\"loff\":\"\",\"li_type\":\"in\",\"li_ph\":\"Location\",\"li_req\":\"y\",\"li_nm\":\"Input\"},{\"lid\":\"1680696467429\",\"ls\":\"50\",\"loff\":\"y\",\"li_type\":\"sb\",\"li_req\":\"y\",\"li_variants\":\"\\\\u0420\\\\u043e\\\\u0441\\\\u0441\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0431\\\\u0445\\\\u0430\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0432\\\\u0441\\\\u0442\\\\u0440\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0432\\\\u0441\\\\u0442\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0437\\\\u0435\\\\u0440\\\\u0431\\\\u0430\\\\u0439\\\\u0434\\\\u0436\\\\u0430\\\\u043d\\\\n\\\\u0410\\\\u043b\\\\u0431\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u043b\\\\u0436\\\\u0438\\\\u0440\\\\n\\\\u0410\\\\u043d\\\\u0433\\\\u043e\\\\u043b\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0433\\\\u0443\\\\u0438\\\\u043b\\\\u044c\\\\u044f\\\\n\\\\u0410\\\\u043d\\\\u0434\\\\u043e\\\\u0440\\\\u0440\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0442\\\\u0438\\\\u0433\\\\u0443\\\\u0430 \\\\u0438 \\\\u0411\\\\u0430\\\\u0440\\\\u0431\\\\u0443\\\\u0434\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0442\\\\u0438\\\\u043b\\\\u044c\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0410\\\\u0440\\\\u0433\\\\u0435\\\\u043d\\\\u0442\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0410\\\\u0440\\\\u043c\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0444\\\\u0433\\\\u0430\\\\u043d\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0411\\\\u0430\\\\u0433\\\\u0430\\\\u043c\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0411\\\\u0430\\\\u043d\\\\u0433\\\\u043b\\\\u0430\\\\u0434\\\\u0435\\\\u0448\\\\n\\\\u0411\\\\u0430\\\\u0440\\\\u0431\\\\u0430\\\\u0434\\\\u043e\\\\u0441\\\\n\\\\u0411\\\\u0430\\\\u0445\\\\u0440\\\\u0435\\\\u0439\\\\u043d\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u0430\\\\u0440\\\\u0443\\\\u0441\\\\u044c\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u0438\\\\u0437\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u044c\\\\u0433\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u0435\\\\u043d\\\\u0438\\\\u043d\\\\n\\\\u0411\\\\u0435\\\\u0440\\\\u043c\\\\u0443\\\\u0434\\\\u044b\\\\n\\\\u0411\\\\u043e\\\\u043b\\\\u0433\\\\u0430\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u043e\\\\u043b\\\\u0438\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u043e\\\\u0441\\\\u043d\\\\u0438\\\\u044f\\\\/\\\\u0413\\\\u0435\\\\u0440\\\\u0446\\\\u0435\\\\u0433\\\\u043e\\\\u0432\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0411\\\\u043e\\\\u0442\\\\u0441\\\\u0432\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0411\\\\u0440\\\\u0430\\\\u0437\\\\u0438\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u0412\\\\u0438\\\\u0440\\\\u0433\\\\u0438\\\\u043d\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e-\\\\u0432\\\\u0430\\\\n\\\\u0411\\\\u0440\\\\u0443\\\\u043d\\\\u0435\\\\u0439\\\\n\\\\u0411\\\\u0443\\\\u0440\\\\u043a\\\\u0438\\\\u043d\\\\u0430 \\\\u0424\\\\u0430\\\\u0441\\\\u043e\\\\n\\\\u0411\\\\u0443\\\\u0440\\\\u0443\\\\u043d\\\\u0434\\\\u0438\\\\n\\\\u0411\\\\u0443\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0412\\\\u0430\\\\u043d\\\\u0443\\\\u0430\\\\u0442\\\\u0443\\\\n\\\\u0412\\\\u0430\\\\u0442\\\\u0438\\\\u043a\\\\u0430\\\\u043d\\\\n\\\\u0412\\\\u0435\\\\u043b\\\\u0438\\\\u043a\\\\u043e\\\\u0431\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0412\\\\u0435\\\\u043d\\\\u0433\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0412\\\\u0435\\\\u043d\\\\u0435\\\\u0441\\\\u0443\\\\u044d\\\\u043b\\\\u0430\\\\n\\\\u0412\\\\u044c\\\\u0435\\\\u0442\\\\u043d\\\\u0430\\\\u043c\\\\n\\\\u0413\\\\u0430\\\\u0431\\\\u043e\\\\u043d\\\\n\\\\u0413\\\\u0430\\\\u0438\\\\u0442\\\\u0438\\\\n\\\\u0413\\\\u0430\\\\u0439\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0430\\\\u0434\\\\u0435\\\\u043b\\\\u0443\\\\u043f\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0430\\\\u0442\\\\u0435\\\\u043c\\\\u0430\\\\u043b\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f-\\\\u0411\\\\u0438\\\\u0441\\\\u0430\\\\u0443\\\\n\\\\u0413\\\\u0435\\\\u0440\\\\u043c\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0435\\\\u0440\\\\u043d\\\\u0441\\\\u0438 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u0413\\\\u0438\\\\u0431\\\\u0440\\\\u0430\\\\u043b\\\\u0442\\\\u0430\\\\u0440\\\\n\\\\u0413\\\\u043e\\\\u043d\\\\u0434\\\\u0443\\\\u0440\\\\u0430\\\\u0441\\\\n\\\\u0413\\\\u043e\\\\u043d\\\\u043a\\\\u043e\\\\u043d\\\\u0433\\\\n\\\\u0413\\\\u043e\\\\u0441\\\\u0443\\\\u0434\\\\u0430\\\\u0440\\\\u0441\\\\u0442\\\\u0432\\\\u043e \\\\u041f\\\\u0430\\\\u043b\\\\u0435\\\\u0441\\\\u0442\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u0430\\\\u0434\\\\u0430\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0440\\\\u0443\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0414\\\\u0420 \\\\u041a\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\n\\\\u0414\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0414\\\\u0436\\\\u0435\\\\u0440\\\\u0441\\\\u0438 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u0414\\\\u0436\\\\u0438\\\\u0431\\\\u0443\\\\u0442\\\\u0438\\\\n\\\\u0414\\\\u043e\\\\u043c\\\\u0438\\\\u043d\\\\u0438\\\\u043a\\\\u0430\\\\u043d\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u0420\\\\u0435\\\\u0441\\\\u043f\\\\u0443\\\\u0431\\\\u043b\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u0415\\\\u0433\\\\u0438\\\\u043f\\\\u0435\\\\u0442\\\\n\\\\u0417\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0417\\\\u0430\\\\u043f\\\\u0430\\\\u0434\\\\u043d\\\\u0430\\\\u044f \\\\u0421\\\\u0430\\\\u0445\\\\u0430\\\\u0440\\\\u0430\\\\n\\\\u0417\\\\u0438\\\\u043c\\\\u0431\\\\u0430\\\\u0431\\\\u0432\\\\u0435\\\\n\\\\u0418\\\\u0437\\\\u0440\\\\u0430\\\\u0438\\\\u043b\\\\u044c\\\\n\\\\u0418\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u043d\\\\u0434\\\\u043e\\\\u043d\\\\u0435\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u043e\\\\u0440\\\\u0434\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0440\\\\u0430\\\\u043a\\\\n\\\\u0418\\\\u0440\\\\u0430\\\\u043d\\\\n\\\\u0418\\\\u0440\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0441\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0441\\\\u043f\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0442\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0419\\\\u0435\\\\u043c\\\\u0435\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u0431\\\\u043e-\\\\u0412\\\\u0435\\\\u0440\\\\u0434\\\\u0435\\\\n\\\\u041a\\\\u0430\\\\u0437\\\\u0430\\\\u0445\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u043c\\\\u0431\\\\u043e\\\\u0434\\\\u0436\\\\u0430\\\\n\\\\u041a\\\\u0430\\\\u043c\\\\u0435\\\\u0440\\\\u0443\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u043d\\\\u0430\\\\u0434\\\\u0430\\\\n\\\\u041a\\\\u0430\\\\u0442\\\\u0430\\\\u0440\\\\n\\\\u041a\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041a\\\\u0438\\\\u043f\\\\u0440\\\\n\\\\u041a\\\\u0438\\\\u0442\\\\u0430\\\\u0439\\\\n\\\\u041a\\\\u043e\\\\u043b\\\\u0443\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u041a\\\\u043e\\\\u0441\\\\u0442\\\\u0430-\\\\u0420\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u041a\\\\u043e\\\\u0442-\\\\u0434\\\\u0418\\\\u0432\\\\u0443\\\\u0430\\\\u0440 \\\\u043a\\\\u0443\\\\u0431\\\\u0430\\\\n\\\\u041a\\\\u0443\\\\u0432\\\\u0435\\\\u0439\\\\u0442\\\\n\\\\u041a\\\\u0443\\\\u043a\\\\u0430 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041a\\\\u044b\\\\u0440\\\\u0433\\\\u044b\\\\u0437\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041b\\\\u0430\\\\u043e\\\\u0441\\\\n\\\\u041b\\\\u0430\\\\u0442\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0435\\\\u0441\\\\u043e\\\\u0442\\\\u043e\\\\n\\\\u041b\\\\u0438\\\\u0431\\\\u0435\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0438\\\\u0432\\\\u0430\\\\u043d\\\\n\\\\u041b\\\\u0438\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0438\\\\u0442\\\\u0432\\\\u0430\\\\n\\\\u041b\\\\u0438\\\\u0445\\\\u0442\\\\u0435\\\\u043d\\\\u0448\\\\u0442\\\\u0435\\\\u0439\\\\u043d\\\\n\\\\u041b\\\\u044e\\\\u043a\\\\u0441\\\\u0435\\\\u043c\\\\u0431\\\\u0443\\\\u0440\\\\u0433\\\\n\\\\u041c\\\\u0430\\\\u0432\\\\u0440\\\\u0438\\\\u043a\\\\u0438\\\\u0439\\\\n\\\\u041c\\\\u0430\\\\u0432\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u0434\\\\u0430\\\\u0433\\\\u0430\\\\u0441\\\\u043a\\\\u0430\\\\u0440\\\\n\\\\u041c\\\\u0430\\\\u043a\\\\u0435\\\\u0434\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u0430\\\\u0439\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u0438\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u044c\\\\u0434\\\\u0438\\\\u0432\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u044c\\\\u0442\\\\u0430\\\\n\\\\u041c\\\\u0430\\\\u0440\\\\u043e\\\\u043a\\\\u043a\\\\u043e\\\\n\\\\u041c\\\\u0435\\\\u043a\\\\u0441\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u041c\\\\u043e\\\\u0437\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u043a\\\\n\\\\u041c\\\\u043e\\\\u043b\\\\u0434\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041c\\\\u043e\\\\u043d\\\\u0430\\\\u043a\\\\u043e\\\\n\\\\u041c\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u044c\\\\u044f\\\\u043d\\\\u043c\\\\u0430 (\\\\u0411\\\\u0438\\\\u0440\\\\u043c\\\\u0430)\\\\n\\\\u041c\\\\u044d\\\\u043d \\\\u043e-\\\\u0432\\\\n\\\\u041d\\\\u0430\\\\u043c\\\\u0438\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u0435\\\\u043f\\\\u0430\\\\u043b\\\\n\\\\u041d\\\\u0438\\\\u0433\\\\u0435\\\\u0440\\\\n\\\\u041d\\\\u0438\\\\u0433\\\\u0435\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u0438\\\\u0434\\\\u0435\\\\u0440\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u044b (\\\\u0413\\\\u043e\\\\u043b\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f)\\\\n\\\\u041d\\\\u0438\\\\u043a\\\\u0430\\\\u0440\\\\u0430\\\\u0433\\\\u0443\\\\u0430\\\\n\\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u0417\\\\u0435\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u041a\\\\u0430\\\\u043b\\\\u0435\\\\u0434\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u043e\\\\u0440\\\\u0432\\\\u0435\\\\u0433\\\\u0438\\\\u044f\\\\nO.A.\\\\u042d.\\\\n\\\\u041e\\\\u043c\\\\u0430\\\\u043d\\\\n\\\\u041f\\\\u0430\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041f\\\\u0430\\\\u043b\\\\u0430\\\\u0443\\\\n\\\\u041f\\\\u0430\\\\u043d\\\\u0430\\\\u043c\\\\u0430\\\\n\\\\u041f\\\\u0430\\\\u043f\\\\u0443\\\\u0430 \\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u041f\\\\u0430\\\\u0440\\\\u0430\\\\u0433\\\\u0432\\\\u0430\\\\u0439\\\\n\\\\u041f\\\\u0435\\\\u0440\\\\u0443\\\\n\\\\u041f\\\\u0438\\\\u0442\\\\u043a\\\\u044d\\\\u0440\\\\u043d \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u041f\\\\u043e\\\\u043b\\\\u044c\\\\u0448\\\\u0430\\\\n\\\\u041f\\\\u043e\\\\u0440\\\\u0442\\\\u0443\\\\u0433\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u041f\\\\u0443\\\\u044d\\\\u0440\\\\u0442\\\\u043e \\\\u0420\\\\u0438\\\\u043a\\\\u043e\\\\n\\\\u0420\\\\u0435\\\\u0441\\\\u043f\\\\u0443\\\\u0431\\\\u043b\\\\u0438\\\\u043a\\\\u0430 \\\\u041a\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\n\\\\u0420\\\\u0435\\\\u044e\\\\u043d\\\\u044c\\\\u043e\\\\u043d\\\\n\\\\u0420\\\\u0443\\\\u0430\\\\u043d\\\\u0434\\\\u0430\\\\n\\\\u0420\\\\u0443\\\\u043c\\\\u044b\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0428\\\\u0410\\\\n\\\\u0421\\\\u0430\\\\u043b\\\\u044c\\\\u0432\\\\u0430\\\\u0434\\\\u043e\\\\u0440\\\\n\\\\u0421\\\\u0430\\\\u043c\\\\u043e\\\\u0430\\\\n\\\\u0421\\\\u0430\\\\u043d-\\\\u041c\\\\u0430\\\\u0440\\\\u0438\\\\u043d\\\\u043e\\\\n\\\\u0421\\\\u0430\\\\u043d-\\\\u0422\\\\u043e\\\\u043c\\\\u0435 \\\\u0438 \\\\u041f\\\\u0440\\\\u0438\\\\u043d\\\\u0441\\\\u0438\\\\u043f\\\\u0438\\\\n\\\\u0421\\\\u0430\\\\u0443\\\\u0434\\\\u043e\\\\u0432\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u0410\\\\u0440\\\\u0430\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0432\\\\u0430\\\\u0437\\\\u0438\\\\u043b\\\\u0435\\\\u043d\\\\u0434\\\\n\\\\u0421\\\\u0432\\\\u044f\\\\u0442\\\\u0430\\\\u044f \\\\u041b\\\\u044e\\\\u0441\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0435\\\\u0432\\\\u0435\\\\u0440\\\\u043d\\\\u0430\\\\u044f \\\\u041a\\\\u043e\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u0421\\\\u0435\\\\u0439\\\\u0448\\\\u0435\\\\u043b\\\\u043b\\\\u044b\\\\n\\\\u0421\\\\u0435\\\\u043d-\\\\u041f\\\\u044c\\\\u0435\\\\u0440 \\\\u0438 \\\\u041c\\\\u0438\\\\u043a\\\\u0435\\\\u043b\\\\u043e\\\\u043d\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0435\\\\u0433\\\\u0430\\\\u043b\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0442 \\\\u041a\\\\u0438\\\\u0442\\\\u0441 \\\\u0438 \\\\u041d\\\\u0435\\\\u0432\\\\u0438\\\\u0441\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0442-\\\\u0412\\\\u0438\\\\u043d\\\\u0441\\\\u0435\\\\u043d\\\\u0442 \\\\u0438 \\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u0430\\\\u0434\\\\u0438\\\\u043d\\\\u044b\\\\n\\\\u0421\\\\u0435\\\\u0440\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0438\\\\u043d\\\\u0433\\\\u0430\\\\u043f\\\\u0443\\\\u0440\\\\n\\\\u0421\\\\u0438\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043b\\\\u043e\\\\u0432\\\\u0430\\\\u043a\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043b\\\\u043e\\\\u0432\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043e\\\\u043b\\\\u043e\\\\u043c\\\\u043e\\\\u043d\\\\u043e\\\\u0432\\\\u044b \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0421\\\\u043e\\\\u043c\\\\u0430\\\\u043b\\\\u0438\\\\n\\\\u0421\\\\u0443\\\\u0434\\\\u0430\\\\u043d\\\\n\\\\u0421\\\\u0443\\\\u0440\\\\u0438\\\\u043d\\\\u0430\\\\u043c\\\\n\\\\u0421\\\\u044c\\\\u0435\\\\u0440\\\\u0440\\\\u0430-\\\\u041b\\\\u0435\\\\u043e\\\\u043d\\\\u0435\\\\n\\\\u0422\\\\u0430\\\\u0434\\\\u0436\\\\u0438\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0422\\\\u0430\\\\u0438\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\n\\\\u0422\\\\u0430\\\\u0439\\\\u0432\\\\u0430\\\\u043d\\\\u044c\\\\n\\\\u0422\\\\u0430\\\\u043d\\\\u0437\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0422\\\\u043e\\\\u0433\\\\u043e\\\\n\\\\u0422\\\\u0440\\\\u0438\\\\u043d\\\\u0438\\\\u0434\\\\u0430\\\\u0434 \\\\u0438 \\\\u0422\\\\u043e\\\\u0431\\\\u0430\\\\u0433\\\\u043e\\\\n\\\\u0422\\\\u0443\\\\u0432\\\\u0430\\\\u043b\\\\u0443\\\\n\\\\u0422\\\\u0443\\\\u043d\\\\u0438\\\\u0441\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u043a\\\\u043c\\\\u0435\\\\u043d\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u043a\\\\u0441 \\\\u0438 \\\\u041a\\\\u0435\\\\u0439\\\\u043a\\\\u043e\\\\u0441\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0423\\\\u0433\\\\u0430\\\\u043d\\\\u0434\\\\u0430\\\\n\\\\u0423\\\\u0437\\\\u0431\\\\u0435\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0423\\\\u043a\\\\u0440\\\\u0430\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0423\\\\u043e\\\\u043b\\\\u043b\\\\u0438\\\\u0441 \\\\u0438 \\\\u0424\\\\u0443\\\\u0442\\\\u0443\\\\u043d\\\\u0430 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0423\\\\u0440\\\\u0443\\\\u0433\\\\u0432\\\\u0430\\\\u0439\\\\n\\\\u0424\\\\u0430\\\\u0440\\\\u0435\\\\u0440\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0424\\\\u0438\\\\u0434\\\\u0436\\\\u0438\\\\n\\\\u0424\\\\u0438\\\\u043b\\\\u0438\\\\u043f\\\\u043f\\\\u0438\\\\u043d\\\\u044b\\\\n\\\\u0424\\\\u0438\\\\u043d\\\\u043b\\\\u044f\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0424\\\\u0440\\\\u0430\\\\u043d\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0424\\\\u0440\\\\u0430\\\\u043d\\\\u0446\\\\u0443\\\\u0437\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u041f\\\\u043e\\\\u043b\\\\u0438\\\\u043d\\\\u0435\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0425\\\\u043e\\\\u0440\\\\u0432\\\\u0430\\\\u0442\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0430\\\\u0434\\\\n\\\\u0427\\\\u0435\\\\u0440\\\\u043d\\\\u043e\\\\u0433\\\\u043e\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0435\\\\u0445\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0438\\\\u043b\\\\u0438\\\\n\\\\u0428\\\\u0432\\\\u0435\\\\u0439\\\\u0446\\\\u0430\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0428\\\\u0432\\\\u0435\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0428\\\\u0440\\\\u0438-\\\\u041b\\\\u0430\\\\u043d\\\\u043a\\\\u0430\\\\n\\\\u042d\\\\u043a\\\\u0432\\\\u0430\\\\u0434\\\\u043e\\\\u0440\\\\n\\\\u042d\\\\u043a\\\\u0432\\\\u0430\\\\u0442\\\\u043e\\\\u0440\\\\u0438\\\\u0430\\\\u043b\\\\u044c\\\\u043d\\\\u0430\\\\u044f \\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u042d\\\\u0440\\\\u0438\\\\u0442\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u042d\\\\u0441\\\\u0442\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u042d\\\\u0444\\\\u0438\\\\u043e\\\\u043f\\\\u0438\\\\u044f\\\\n\\\\u042e\\\\u0410\\\\u0420\\\\n\\\\u042e\\\\u0436\\\\u043d\\\\u0430\\\\u044f \\\\u041a\\\\u043e\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u042e\\\\u0436\\\\u043d\\\\u0430\\\\u044f \\\\u041e\\\\u0441\\\\u0435\\\\u0442\\\\u0438\\\\u044f\\\\n\\\\u042f\\\\u043c\\\\u0430\\\\u0439\\\\u043a\\\\u0430\\\\n\\\\u042f\\\\u043f\\\\u043e\\\\u043d\\\\u0438\\\\u044f\",\"li_nm\":\"Selectbox\"},{\"lid\":\"1680697019488\",\"ls\":\"60\",\"loff\":\"\",\"li_type\":\"ta\",\"li_ph\":\"Please provide any additional information regarding your clinical or research inquiry.\",\"li_req\":\"y\",\"li_rows\":\"3\",\"li_nm\":\"Textarea\"},{\"lid\":\"1680697037405\",\"ls\":\"70\",\"loff\":\"\",\"li_type\":\"cb\",\"li_req\":\"y\",\"li_label\":\"I consent to the processing of my personal data.\",\"li_checked\":\"y\",\"li_nm\":\"Checkbox\"}]\\nLearn more aboutOncobox\\n![](https://static.tildacdn.com/tild3738-3464-4333-b061-663736366136/3.png)\\nJoin us in pushing the boundaries of clinical and research development. From groundbreaking clinical trials to pioneering biomarker and CDx advancements, we\\'re dedicated to transforming cancer care and improving patient outcomes. Ready to make a difference? Reach out and let\\'s collaborate!\\n[](http://oncobox.com/<#closepopup>)\\nYour inquiry has been submitted. Our team will contact you shortly.\\n[](http://oncobox.com/<#closepopup>)\\n![](https://static.tildacdn.com/tild3065-3139-4230-b365-323236393664/Group_1790.svg)\\n![](https://static.tildacdn.com/tild6563-3061-4839-b864-323966346139/Group_1793.svg)\\n2015\\n2017\\n2018\\n2020\\n2023\\nCompany Inception\\nY Combinator\\nDiagnostic Platform Launch & Key Research Publication\\nUnique Biobank Collection & Clinical Trials Launch\\nClinical Trial Completion & US Patent Acquisition\\nFounded with the mission to revolutionize the field of precision oncology, leveraging cutting-edge system biology and omics technologies.\\nA major milestone for the company, highlighting its pioneering efforts in oncodiagnostics and greatly accelerating its business development.\\nIntroduced a platform that enhances the precision of cancer treatment. A paper in Seminars in Cancer Biology detailed its scientific principles and efficacy.\\nObtained unique gene expression profiles from healthy tissues, partially published in Nature Scientific Data. Initiated a multicentral prospective clinical trial.\\nConcluded a prospective trial with 250 patients, yielding promising results, with publication preparation underway. Additionally, secured a patent from the USPTO.\\n![](https://static.tildacdn.com/tild6532-3432-4337-a363-666330643337/2.png)\\n![](https://static.tildacdn.com/tild3166-3461-4664-b631-396533393731/3.png)\\n![](https://static.tildacdn.com/tild6538-6335-4433-a134-386234343538/4.png)\\n![](https://static.tildacdn.com/tild6232-3333-4265-a137-653431323036/5.png)\\n![](https://static.tildacdn.com/tild3835-3131-4361-a335-356238643238/9.png)\\n![](https://static.tildacdn.com/tild6663-3730-4236-b463-323638356135/8.png)\\n![](https://static.tildacdn.com/tild3261-3830-4930-a130-393461663933/1.png)\\n![](https://static.tildacdn.com/tild3130-3966-4330-b730-346632376661/7.png)\\n![](https://static.tildacdn.com/tild6661-3431-4662-a439-623139633734/6.png)\\nNews\\nOncobox will present the findings of a prospective clinical trial NCT03724097 on the prescription of anticancer drugs using RNA sequencing and the Oncobox platform at the [WIN Symposium](http://oncobox.com/<https:/win-burjeel-symposium.com/>), endorsed by ASCO, in Abu Dhabi, UAE, on March 1, 2024.\\nWIN Symposium 2024: Results of Prospective Clinical Study\\nOncobox has been granted a U.S. patent for the advanced genetic information analysis platform! This milestone not only underscores our commitment to innovation in personalized medicine but also sets a new standard in genetic diagnostics using RNA.\\nPioneered a[ machine learning approach](http://oncobox.com/<https:/www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.652063/full>) to identify gene markers that predict the effectiveness of bortezomib in treating multiple myeloma. This breakthrough, featuring key biomarkers like FGFR3 and MAF, promises more tailored and effective treatments for this widespread cancer in the elderly.\\nOncobox Secures US Patent for Cutting-Edge Genetic Platform\\nOncobox Unveils ML-Powered Breakthrough in Myeloma Therapy\\n15 February 2024\\n20 April 2023\\n06 November 2022\\n[![](https://static.tildacdn.com/tild3533-3866-4733-b835-633931316362/logo_white.svg)](http://oncobox.com/<#first>)\\nThe research is supported by grants from Amazon and Microsoft.\\nhello@oncobox.com\\n![](https://static.tildacdn.com/tild3835-6561-4865-b033-393433343635/Group_1628.svg)\\n![](https://static.tildacdn.com/tild6132-3634-4361-a631-316136383963/Group_1629.svg)\\n' markdown_with_citations='To main content⟨1⟩\\n[](http://oncobox.com/</login>)\\nDiagnostics⟨2⟩\\nClinical effectiveness⟨3⟩\\nResearch⟨4⟩\\nAbout⟨5⟩\\n![⟨6⟩](http://oncobox.com/<#first>)\\n![⟨7⟩](http://oncobox.com/<#menuopen>)\\n![](https://static.tildacdn.com/tild3331-3865-4363-a163-323065326431/oncobox_logo_white.svg)\\nLog in⟨8⟩\\n![⟨9⟩](http://oncobox.com/</login>)\\n![](https://static.tildacdn.com/tild6564-3731-4164-b934-366139383534/oncobox_logo_white.svg)\\n  * Diagnostics⟨2⟩\\n  * Clinical effectiveness⟨3⟩\\n  * Research⟨4⟩\\n  * About⟨5⟩\\n\\n\\n[](http://oncobox.com/</login>)Log in  \\n---  \\n![](https://static.tildacdn.com/tild3163-3739-4639-a265-313266373536/12.png)\\n[](http://oncobox.com/</login>)\\n![](https://static.tildacdn.com/tild6535-3630-4236-b761-613238653331/13-3.png)\\n![](https://static.tildacdn.com/tild3731-3565-4830-b838-656238633733/12.png)\\n![](https://static.tildacdn.com/tild3066-3437-4934-b363-653637336634/11.png)\\nEffective cancer therapybased on tumor deep molecular profiling\\n![](https://static.tildacdn.com/tild3564-3962-4465-a339-306137643963/2.svg)\\nEvery tumor is unique, and at Oncobox, we\\'ve pioneered a groundbreaking solution to ensure the treatment is as exceptional as each individual.Oncobox Dx considers all molecular nuances of a tumor and evaluates the effectiveness of 170 novel targeted and immunotherapy drugs, assisting the healthcare provider in crafting a highly effective treatment plan.Let\\'s elevate cancer care with unparalleled precision.\\nDiagnostics⟨10⟩\\nClinical effectiveness⟨11⟩\\nResearch⟨12⟩\\nAbout⟨13⟩\\n![](https://static.tildacdn.com/tild6434-6565-4837-a534-656434616538/oncobox_logo.svg)\\n![⟨7⟩](http://oncobox.com/<#menuopen>)\\n![](https://static.tildacdn.com/tild6336-6233-4132-b639-346638333639/logo_white.svg)\\nLog in⟨8⟩\\n![⟨14⟩](http://oncobox.com/</login>)\\n[](http://oncobox.com/<#test>)\\nLearn more⟨15⟩\\n![⟨14⟩](http://oncobox.com/<#test>)\\n![](https://static.tildacdn.com/tild6462-6664-4638-a532-663938626663/11.png)\\n![](https://static.tildacdn.com/tild3665-3135-4439-a662-373161656438/Subtract.svg)\\n![](https://static.tildacdn.com/tild3639-3632-4361-a336-666430626233/13.svg)\\n![](https://static.tildacdn.com/tild3930-3162-4561-b435-643635633030/12.png)\\nYou can access Oncobox testing by consulting with an oncologist at one of our affiliated clinics. This process typically involves sending a tumor sample to our laboratory for comprehensive genomic profiling.\\n01\\nThe report provides a detailed list of molecular abnormalities, ranks the drugs accordingly, and includes outcomes from clinical trials. This information empowers the physician or medical board to devise the most effective treatment strategy.\\n03\\nThe testing includes analysis of changes in DNA and RNA obtained from a tumor sample. Oncobox predicts the efficacy of over 170 targeted and immunotherapeutic drugs and generates a personalized drug ranking tailored to the specific patient.\\n02\\n![](https://static.tildacdn.com/tild3238-6561-4035-b335-376136366130/scene_02_eng_676453.png)\\n![](https://static.tildacdn.com/tild3430-6565-4065-a461-316465396133/Group_1732.png)\\n![](https://static.tildacdn.com/tild3365-6462-4234-a239-316637646266/A4_paper_eng.png)\\nClinical efficacy ofOncobox Dx\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨16⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n![⟨17⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\nBiomedicines⟨18⟩\\n![⟨19⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨20⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n![⟨21⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\nExperimental Hematology & Oncology⟨22⟩\\n![⟨19⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨23⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\novarian cancer\\nFemale, 40 years\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![](https://static.tildacdn.com/tild3762-3762-4132-a564-616366663561/verified-logo-2-2_2.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nOncobox analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient’s disease.\\n![⟨24⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\nCSH Molecular Case Studies⟨25⟩\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![⟨19⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨26⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nlung cancer\\nMale, 48 years\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild3432-3534-4565-b930-373331626463/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3837-3264-4366-b732-376638333634/verified-logo-1_4.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nSurvival of our patient after developing resistance to ALK inhibitor was longer for 16 months than previously reported average survival for such cases.\\n![⟨27⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\nFrontiers in Oncology⟨28⟩\\n![⟨19⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨16⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n![⟨17⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\nBiomedicines⟨18⟩\\n![⟨19⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨20⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n![⟨21⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\nExperimental Hematology & Oncology⟨22⟩\\n![⟨19⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨23⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\novarian cancer\\nFemale, 40 years\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![](https://static.tildacdn.com/tild3762-3762-4132-a564-616366663561/verified-logo-2-2_2.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nOncobox analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient’s disease.\\n![⟨24⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n[](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\nCSH Molecular Case Studies⟨25⟩\\nBased on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.\\n![⟨19⟩](http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨26⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nlung cancer\\nMale, 48 years\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild3432-3534-4565-b930-373331626463/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.\\nBased on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient\\'s condition and a progression-free survival of 2 years.\\n![](https://static.tildacdn.com/tild3837-3264-4366-b732-376638333634/verified-logo-1_4.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\nSurvival of our patient after developing resistance to ALK inhibitor was longer for 16 months than previously reported average survival for such cases.\\n![⟨27⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\nFrontiers in Oncology⟨28⟩\\n![⟨19⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨16⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\nstomach cancer\\nFemale, 79 years\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6435-6638-4536-a435-306532666166/Subtract.svg)\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.\\nBased on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.\\n![](https://static.tildacdn.com/tild3666-6166-4231-a438-373237396265/verified-logo-3_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years.\"\\n![⟨17⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n[](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\nBiomedicines⟨18⟩\\n![⟨19⟩](http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>)\\n![](https://static.tildacdn.com/tild6439-6663-4433-b864-373164666536/Subtract-1.svg)\\n![](https://static.tildacdn.com/tild6135-6635-4161-a164-653664626163/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild3535-3333-4635-b138-383963343065/photo.svg)\\n![⟨20⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6432-3539-4231-b635-303566303161/Subtract.svg)\\n![](https://static.tildacdn.com/tild6133-6530-4235-b537-356466353361/dsd.svg)\\n![](https://static.tildacdn.com/tild6165-6330-4437-a132-623665666566/Rectangle_1119.svg)\\n![](https://static.tildacdn.com/tild6137-6332-4035-b339-613033323037/2.svg)\\n![](https://static.tildacdn.com/tild3363-3536-4530-b765-626130353266/photo.svg)\\ncholangiocarcinoma\\nMale, 72 years\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n![](https://static.tildacdn.com/tild6238-6561-4163-b537-303261613438/Subtract.svg)\\nThe patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient\\'s condition worsened.\\nBased on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient\\'s condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.\\n![](https://static.tildacdn.com/tild3835-3834-4036-b061-306534363964/v-4_1.png)\\n![](https://static.tildacdn.com/tild3636-3166-4638-a339-313665346462/photo.svg)\\nContinue reading on:\\n\"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.\"\\n![⟨21⟩](http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>)\\n[](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\nExperimental Hematology & Oncology⟨22⟩\\n![⟨19⟩](http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>)\\n![](https://static.tildacdn.com/tild6633-3636-4666-b964-636538643439/arrow-left.svg)\\n![](https://static.tildacdn.com/tild6438-6238-4534-a531-316566306531/arrow-right.svg)\\n![](https://static.tildacdn.com/tild3564-3934-4434-a563-366139643561/Subtract.svg)\\n![](https://static.tildacdn.com/tild3766-3934-4639-b832-343533396135/Group_1788.svg)\\n![](https://static.tildacdn.com/tild6136-6636-4664-a265-326136616131/Group_1789.svg)\\n![](https://static.tildacdn.com/tild3566-3433-4232-a534-323962666261/Group_1792.svg)\\n![](https://static.tildacdn.com/tild3933-3034-4463-a431-373866616364/asco-logo-header-des.png)\\nThe effectiveness of Oncobox technology has been validated through both retrospective and prospective clinical studies. In these trials, hundreds of late-stage cancer patients received personalized recommendations for targeted drugs based on their individual DNA & RNA profiling and Oncobox ratings, demonstrating the clinical impact of our solution.\\n![](https://static.tildacdn.com/tild3135-3633-4639-a462-356662313865/header-8e0456ae95ea8.png)\\n![](https://static.tildacdn.com/tild6466-6338-4162-a233-393664616166/Group_1593.png)\\n![](https://static.tildacdn.com/tild3231-3236-4835-a432-623335336131/verified-logo-1_2.png)\\n![](https://static.tildacdn.com/tild3330-3933-4064-b936-653632323363/Seminars_in_Cancer_B.png)\\nView articles⟨29⟩\\n![⟨30⟩](http://oncobox.com/<https:/oncobox.ru/our_research.html>)\\n![](https://static.tildacdn.com/tild3734-6430-4362-a361-343066353231/Subtract.svg)\\n![](https://static.tildacdn.com/tild3764-3362-4432-b331-346632626530/Subtract.svg)\\n![](https://static.tildacdn.com/tild6438-6565-4236-b137-653265613866/Subtract.svg)\\n![](https://static.tildacdn.com/tild3931-3364-4437-b162-613132343666/Subtract.svg)\\nOncobox Diagnostics\\n![](https://static.tildacdn.com/tild3166-3833-4433-b361-643439653332/box___flyer_eng.png)\\n![](https://static.tildacdn.com/tild6131-3135-4234-a463-386135396166/1_-_Group_1695.svg)\\n![](https://static.tildacdn.com/tild3135-3366-4130-b034-343766373732/2_-_Group_1696.svg)\\n![](https://static.tildacdn.com/tild6139-3637-4437-b237-346439616434/3_-_Group_1697.svg)\\n![](https://static.tildacdn.com/tild3639-3738-4438-b538-613963323937/4_-_Group_1698.svg)\\n![](https://static.tildacdn.com/tild3332-6630-4365-b263-633165373236/5_-_Group_1699.svg)\\n![](https://static.tildacdn.com/tild6562-6532-4664-b636-633639333963/6_-_Group_1700.svg)\\n![⟨31⟩](http://oncobox.com/<https:/oncobox.ru/materials/oncobox_report.pdf>)\\n![](https://static.tildacdn.com/tild3835-6463-4664-a433-633830613036/Group_1648_5.svg)\\n![](https://static.tildacdn.com/tild3433-6266-4065-b539-666435366433/Group_1648_2.svg)\\n![](https://static.tildacdn.com/tild3336-3636-4439-a630-616131303330/Group_1648_3.svg)\\n![](https://static.tildacdn.com/tild3530-6363-4530-b963-383836643065/Group_1648_6.svg)\\n![](https://static.tildacdn.com/tild3434-3339-4362-b435-626537323466/Group_1648_4.svg)\\n![⟨32⟩](http://oncobox.com/<#popuppdf3>)\\n![⟨33⟩](http://oncobox.com/<#popuppdf3>)\\n![](https://static.tildacdn.com/tild3134-6137-4233-a563-323064313036/Group_1648_1.svg)\\n![](https://static.tildacdn.com/tild3561-6231-4162-a363-386661353637/2.png)\\n![](https://static.tildacdn.com/tild3530-6637-4965-b934-393639633061/Subtract.png)\\nI consent to the processing of my personal data.\\nSubmit\\n[{\"lid\":\"1531306540094\",\"ls\":\"10\",\"loff\":\"\",\"li_type\":\"nm\",\"li_name\":\"name\",\"li_ph\":\"Name\",\"li_req\":\"y\",\"li_nm\":\"name\"},{\"lid\":\"1680696408713\",\"ls\":\"20\",\"loff\":\"\",\"li_type\":\"ph\",\"li_ph\":\"\\\\u0422\\\\u0435\\\\u043b\\\\u0435\\\\u0444\\\\u043e\\\\u043d\",\"li_masktype\":\"a\",\"li_nm\":\"Phone\"},{\"lid\":\"1531306243545\",\"ls\":\"30\",\"loff\":\"\",\"li_type\":\"em\",\"li_name\":\"examplemail.com\",\"li_ph\":\"Email\",\"li_req\":\"y\",\"li_nm\":\"examplemail.com\"},{\"lid\":\"1688043139550\",\"ls\":\"40\",\"loff\":\"\",\"li_type\":\"in\",\"li_ph\":\"Location\",\"li_req\":\"y\",\"li_nm\":\"Input\"},{\"lid\":\"1680696467429\",\"ls\":\"50\",\"loff\":\"y\",\"li_type\":\"sb\",\"li_req\":\"y\",\"li_variants\":\"\\\\u0420\\\\u043e\\\\u0441\\\\u0441\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0431\\\\u0445\\\\u0430\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0432\\\\u0441\\\\u0442\\\\u0440\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0432\\\\u0441\\\\u0442\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0437\\\\u0435\\\\u0440\\\\u0431\\\\u0430\\\\u0439\\\\u0434\\\\u0436\\\\u0430\\\\u043d\\\\n\\\\u0410\\\\u043b\\\\u0431\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u043b\\\\u0436\\\\u0438\\\\u0440\\\\n\\\\u0410\\\\u043d\\\\u0433\\\\u043e\\\\u043b\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0433\\\\u0443\\\\u0438\\\\u043b\\\\u044c\\\\u044f\\\\n\\\\u0410\\\\u043d\\\\u0434\\\\u043e\\\\u0440\\\\u0440\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0442\\\\u0438\\\\u0433\\\\u0443\\\\u0430 \\\\u0438 \\\\u0411\\\\u0430\\\\u0440\\\\u0431\\\\u0443\\\\u0434\\\\u0430\\\\n\\\\u0410\\\\u043d\\\\u0442\\\\u0438\\\\u043b\\\\u044c\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0410\\\\u0440\\\\u0433\\\\u0435\\\\u043d\\\\u0442\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0410\\\\u0440\\\\u043c\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0410\\\\u0444\\\\u0433\\\\u0430\\\\u043d\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0411\\\\u0430\\\\u0433\\\\u0430\\\\u043c\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0411\\\\u0430\\\\u043d\\\\u0433\\\\u043b\\\\u0430\\\\u0434\\\\u0435\\\\u0448\\\\n\\\\u0411\\\\u0430\\\\u0440\\\\u0431\\\\u0430\\\\u0434\\\\u043e\\\\u0441\\\\n\\\\u0411\\\\u0430\\\\u0445\\\\u0440\\\\u0435\\\\u0439\\\\u043d\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u0430\\\\u0440\\\\u0443\\\\u0441\\\\u044c\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u0438\\\\u0437\\\\n\\\\u0411\\\\u0435\\\\u043b\\\\u044c\\\\u0433\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u0435\\\\u043d\\\\u0438\\\\u043d\\\\n\\\\u0411\\\\u0435\\\\u0440\\\\u043c\\\\u0443\\\\u0434\\\\u044b\\\\n\\\\u0411\\\\u043e\\\\u043b\\\\u0433\\\\u0430\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u043e\\\\u043b\\\\u0438\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u043e\\\\u0441\\\\u043d\\\\u0438\\\\u044f\\\\/\\\\u0413\\\\u0435\\\\u0440\\\\u0446\\\\u0435\\\\u0433\\\\u043e\\\\u0432\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0411\\\\u043e\\\\u0442\\\\u0441\\\\u0432\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0411\\\\u0440\\\\u0430\\\\u0437\\\\u0438\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0411\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u0412\\\\u0438\\\\u0440\\\\u0433\\\\u0438\\\\u043d\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e-\\\\u0432\\\\u0430\\\\n\\\\u0411\\\\u0440\\\\u0443\\\\u043d\\\\u0435\\\\u0439\\\\n\\\\u0411\\\\u0443\\\\u0440\\\\u043a\\\\u0438\\\\u043d\\\\u0430 \\\\u0424\\\\u0430\\\\u0441\\\\u043e\\\\n\\\\u0411\\\\u0443\\\\u0440\\\\u0443\\\\u043d\\\\u0434\\\\u0438\\\\n\\\\u0411\\\\u0443\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0412\\\\u0430\\\\u043d\\\\u0443\\\\u0430\\\\u0442\\\\u0443\\\\n\\\\u0412\\\\u0430\\\\u0442\\\\u0438\\\\u043a\\\\u0430\\\\u043d\\\\n\\\\u0412\\\\u0435\\\\u043b\\\\u0438\\\\u043a\\\\u043e\\\\u0431\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0412\\\\u0435\\\\u043d\\\\u0433\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0412\\\\u0435\\\\u043d\\\\u0435\\\\u0441\\\\u0443\\\\u044d\\\\u043b\\\\u0430\\\\n\\\\u0412\\\\u044c\\\\u0435\\\\u0442\\\\u043d\\\\u0430\\\\u043c\\\\n\\\\u0413\\\\u0430\\\\u0431\\\\u043e\\\\u043d\\\\n\\\\u0413\\\\u0430\\\\u0438\\\\u0442\\\\u0438\\\\n\\\\u0413\\\\u0430\\\\u0439\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0430\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0430\\\\u0434\\\\u0435\\\\u043b\\\\u0443\\\\u043f\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0430\\\\u0442\\\\u0435\\\\u043c\\\\u0430\\\\u043b\\\\u0430\\\\n\\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f-\\\\u0411\\\\u0438\\\\u0441\\\\u0430\\\\u0443\\\\n\\\\u0413\\\\u0435\\\\u0440\\\\u043c\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0435\\\\u0440\\\\u043d\\\\u0441\\\\u0438 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u0413\\\\u0438\\\\u0431\\\\u0440\\\\u0430\\\\u043b\\\\u0442\\\\u0430\\\\u0440\\\\n\\\\u0413\\\\u043e\\\\u043d\\\\u0434\\\\u0443\\\\u0440\\\\u0430\\\\u0441\\\\n\\\\u0413\\\\u043e\\\\u043d\\\\u043a\\\\u043e\\\\u043d\\\\u0433\\\\n\\\\u0413\\\\u043e\\\\u0441\\\\u0443\\\\u0434\\\\u0430\\\\u0440\\\\u0441\\\\u0442\\\\u0432\\\\u043e \\\\u041f\\\\u0430\\\\u043b\\\\u0435\\\\u0441\\\\u0442\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u0430\\\\u0434\\\\u0430\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0440\\\\u0435\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0413\\\\u0440\\\\u0443\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0414\\\\u0420 \\\\u041a\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\n\\\\u0414\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0414\\\\u0436\\\\u0435\\\\u0440\\\\u0441\\\\u0438 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u0414\\\\u0436\\\\u0438\\\\u0431\\\\u0443\\\\u0442\\\\u0438\\\\n\\\\u0414\\\\u043e\\\\u043c\\\\u0438\\\\u043d\\\\u0438\\\\u043a\\\\u0430\\\\u043d\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u0420\\\\u0435\\\\u0441\\\\u043f\\\\u0443\\\\u0431\\\\u043b\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u0415\\\\u0433\\\\u0438\\\\u043f\\\\u0435\\\\u0442\\\\n\\\\u0417\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0417\\\\u0430\\\\u043f\\\\u0430\\\\u0434\\\\u043d\\\\u0430\\\\u044f \\\\u0421\\\\u0430\\\\u0445\\\\u0430\\\\u0440\\\\u0430\\\\n\\\\u0417\\\\u0438\\\\u043c\\\\u0431\\\\u0430\\\\u0431\\\\u0432\\\\u0435\\\\n\\\\u0418\\\\u0437\\\\u0440\\\\u0430\\\\u0438\\\\u043b\\\\u044c\\\\n\\\\u0418\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u043d\\\\u0434\\\\u043e\\\\u043d\\\\u0435\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u043e\\\\u0440\\\\u0434\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0440\\\\u0430\\\\u043a\\\\n\\\\u0418\\\\u0440\\\\u0430\\\\u043d\\\\n\\\\u0418\\\\u0440\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0441\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0441\\\\u043f\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0418\\\\u0442\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u0419\\\\u0435\\\\u043c\\\\u0435\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u0431\\\\u043e-\\\\u0412\\\\u0435\\\\u0440\\\\u0434\\\\u0435\\\\n\\\\u041a\\\\u0430\\\\u0437\\\\u0430\\\\u0445\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u043c\\\\u0431\\\\u043e\\\\u0434\\\\u0436\\\\u0430\\\\n\\\\u041a\\\\u0430\\\\u043c\\\\u0435\\\\u0440\\\\u0443\\\\u043d\\\\n\\\\u041a\\\\u0430\\\\u043d\\\\u0430\\\\u0434\\\\u0430\\\\n\\\\u041a\\\\u0430\\\\u0442\\\\u0430\\\\u0440\\\\n\\\\u041a\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041a\\\\u0438\\\\u043f\\\\u0440\\\\n\\\\u041a\\\\u0438\\\\u0442\\\\u0430\\\\u0439\\\\n\\\\u041a\\\\u043e\\\\u043b\\\\u0443\\\\u043c\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u041a\\\\u043e\\\\u0441\\\\u0442\\\\u0430-\\\\u0420\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u041a\\\\u043e\\\\u0442-\\\\u0434\\\\u0418\\\\u0432\\\\u0443\\\\u0430\\\\u0440 \\\\u043a\\\\u0443\\\\u0431\\\\u0430\\\\n\\\\u041a\\\\u0443\\\\u0432\\\\u0435\\\\u0439\\\\u0442\\\\n\\\\u041a\\\\u0443\\\\u043a\\\\u0430 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041a\\\\u044b\\\\u0440\\\\u0433\\\\u044b\\\\u0437\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041b\\\\u0430\\\\u043e\\\\u0441\\\\n\\\\u041b\\\\u0430\\\\u0442\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0435\\\\u0441\\\\u043e\\\\u0442\\\\u043e\\\\n\\\\u041b\\\\u0438\\\\u0431\\\\u0435\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0438\\\\u0432\\\\u0430\\\\u043d\\\\n\\\\u041b\\\\u0438\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u041b\\\\u0438\\\\u0442\\\\u0432\\\\u0430\\\\n\\\\u041b\\\\u0438\\\\u0445\\\\u0442\\\\u0435\\\\u043d\\\\u0448\\\\u0442\\\\u0435\\\\u0439\\\\u043d\\\\n\\\\u041b\\\\u044e\\\\u043a\\\\u0441\\\\u0435\\\\u043c\\\\u0431\\\\u0443\\\\u0440\\\\u0433\\\\n\\\\u041c\\\\u0430\\\\u0432\\\\u0440\\\\u0438\\\\u043a\\\\u0438\\\\u0439\\\\n\\\\u041c\\\\u0430\\\\u0432\\\\u0440\\\\u0438\\\\u0442\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u0434\\\\u0430\\\\u0433\\\\u0430\\\\u0441\\\\u043a\\\\u0430\\\\u0440\\\\n\\\\u041c\\\\u0430\\\\u043a\\\\u0435\\\\u0434\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u0430\\\\u0439\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u0438\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u044c\\\\u0434\\\\u0438\\\\u0432\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041c\\\\u0430\\\\u043b\\\\u044c\\\\u0442\\\\u0430\\\\n\\\\u041c\\\\u0430\\\\u0440\\\\u043e\\\\u043a\\\\u043a\\\\u043e\\\\n\\\\u041c\\\\u0435\\\\u043a\\\\u0441\\\\u0438\\\\u043a\\\\u0430\\\\n\\\\u041c\\\\u043e\\\\u0437\\\\u0430\\\\u043c\\\\u0431\\\\u0438\\\\u043a\\\\n\\\\u041c\\\\u043e\\\\u043b\\\\u0434\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u041c\\\\u043e\\\\u043d\\\\u0430\\\\u043a\\\\u043e\\\\n\\\\u041c\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u041c\\\\u044c\\\\u044f\\\\u043d\\\\u043c\\\\u0430 (\\\\u0411\\\\u0438\\\\u0440\\\\u043c\\\\u0430)\\\\n\\\\u041c\\\\u044d\\\\u043d \\\\u043e-\\\\u0432\\\\n\\\\u041d\\\\u0430\\\\u043c\\\\u0438\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u0435\\\\u043f\\\\u0430\\\\u043b\\\\n\\\\u041d\\\\u0438\\\\u0433\\\\u0435\\\\u0440\\\\n\\\\u041d\\\\u0438\\\\u0433\\\\u0435\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u0438\\\\u0434\\\\u0435\\\\u0440\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u044b (\\\\u0413\\\\u043e\\\\u043b\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f)\\\\n\\\\u041d\\\\u0438\\\\u043a\\\\u0430\\\\u0440\\\\u0430\\\\u0433\\\\u0443\\\\u0430\\\\n\\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u0417\\\\u0435\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u041a\\\\u0430\\\\u043b\\\\u0435\\\\u0434\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u041d\\\\u043e\\\\u0440\\\\u0432\\\\u0435\\\\u0433\\\\u0438\\\\u044f\\\\nO.A.\\\\u042d.\\\\n\\\\u041e\\\\u043c\\\\u0430\\\\u043d\\\\n\\\\u041f\\\\u0430\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u041f\\\\u0430\\\\u043b\\\\u0430\\\\u0443\\\\n\\\\u041f\\\\u0430\\\\u043d\\\\u0430\\\\u043c\\\\u0430\\\\n\\\\u041f\\\\u0430\\\\u043f\\\\u0443\\\\u0430 \\\\u041d\\\\u043e\\\\u0432\\\\u0430\\\\u044f \\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u041f\\\\u0430\\\\u0440\\\\u0430\\\\u0433\\\\u0432\\\\u0430\\\\u0439\\\\n\\\\u041f\\\\u0435\\\\u0440\\\\u0443\\\\n\\\\u041f\\\\u0438\\\\u0442\\\\u043a\\\\u044d\\\\u0440\\\\u043d \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\n\\\\u041f\\\\u043e\\\\u043b\\\\u044c\\\\u0448\\\\u0430\\\\n\\\\u041f\\\\u043e\\\\u0440\\\\u0442\\\\u0443\\\\u0433\\\\u0430\\\\u043b\\\\u0438\\\\u044f\\\\n\\\\u041f\\\\u0443\\\\u044d\\\\u0440\\\\u0442\\\\u043e \\\\u0420\\\\u0438\\\\u043a\\\\u043e\\\\n\\\\u0420\\\\u0435\\\\u0441\\\\u043f\\\\u0443\\\\u0431\\\\u043b\\\\u0438\\\\u043a\\\\u0430 \\\\u041a\\\\u043e\\\\u043d\\\\u0433\\\\u043e\\\\n\\\\u0420\\\\u0435\\\\u044e\\\\u043d\\\\u044c\\\\u043e\\\\u043d\\\\n\\\\u0420\\\\u0443\\\\u0430\\\\u043d\\\\u0434\\\\u0430\\\\n\\\\u0420\\\\u0443\\\\u043c\\\\u044b\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0428\\\\u0410\\\\n\\\\u0421\\\\u0430\\\\u043b\\\\u044c\\\\u0432\\\\u0430\\\\u0434\\\\u043e\\\\u0440\\\\n\\\\u0421\\\\u0430\\\\u043c\\\\u043e\\\\u0430\\\\n\\\\u0421\\\\u0430\\\\u043d-\\\\u041c\\\\u0430\\\\u0440\\\\u0438\\\\u043d\\\\u043e\\\\n\\\\u0421\\\\u0430\\\\u043d-\\\\u0422\\\\u043e\\\\u043c\\\\u0435 \\\\u0438 \\\\u041f\\\\u0440\\\\u0438\\\\u043d\\\\u0441\\\\u0438\\\\u043f\\\\u0438\\\\n\\\\u0421\\\\u0430\\\\u0443\\\\u0434\\\\u043e\\\\u0432\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u0410\\\\u0440\\\\u0430\\\\u0432\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0432\\\\u0430\\\\u0437\\\\u0438\\\\u043b\\\\u0435\\\\u043d\\\\u0434\\\\n\\\\u0421\\\\u0432\\\\u044f\\\\u0442\\\\u0430\\\\u044f \\\\u041b\\\\u044e\\\\u0441\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0435\\\\u0432\\\\u0435\\\\u0440\\\\u043d\\\\u0430\\\\u044f \\\\u041a\\\\u043e\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u0421\\\\u0435\\\\u0439\\\\u0448\\\\u0435\\\\u043b\\\\u043b\\\\u044b\\\\n\\\\u0421\\\\u0435\\\\u043d-\\\\u041f\\\\u044c\\\\u0435\\\\u0440 \\\\u0438 \\\\u041c\\\\u0438\\\\u043a\\\\u0435\\\\u043b\\\\u043e\\\\u043d\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0435\\\\u0433\\\\u0430\\\\u043b\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0442 \\\\u041a\\\\u0438\\\\u0442\\\\u0441 \\\\u0438 \\\\u041d\\\\u0435\\\\u0432\\\\u0438\\\\u0441\\\\n\\\\u0421\\\\u0435\\\\u043d\\\\u0442-\\\\u0412\\\\u0438\\\\u043d\\\\u0441\\\\u0435\\\\u043d\\\\u0442 \\\\u0438 \\\\u0413\\\\u0440\\\\u0435\\\\u043d\\\\u0430\\\\u0434\\\\u0438\\\\u043d\\\\u044b\\\\n\\\\u0421\\\\u0435\\\\u0440\\\\u0431\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u0438\\\\u043d\\\\u0433\\\\u0430\\\\u043f\\\\u0443\\\\u0440\\\\n\\\\u0421\\\\u0438\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043b\\\\u043e\\\\u0432\\\\u0430\\\\u043a\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043b\\\\u043e\\\\u0432\\\\u0435\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0421\\\\u043e\\\\u043b\\\\u043e\\\\u043c\\\\u043e\\\\u043d\\\\u043e\\\\u0432\\\\u044b \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0421\\\\u043e\\\\u043c\\\\u0430\\\\u043b\\\\u0438\\\\n\\\\u0421\\\\u0443\\\\u0434\\\\u0430\\\\u043d\\\\n\\\\u0421\\\\u0443\\\\u0440\\\\u0438\\\\u043d\\\\u0430\\\\u043c\\\\n\\\\u0421\\\\u044c\\\\u0435\\\\u0440\\\\u0440\\\\u0430-\\\\u041b\\\\u0435\\\\u043e\\\\u043d\\\\u0435\\\\n\\\\u0422\\\\u0430\\\\u0434\\\\u0436\\\\u0438\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0422\\\\u0430\\\\u0438\\\\u043b\\\\u0430\\\\u043d\\\\u0434\\\\n\\\\u0422\\\\u0430\\\\u0439\\\\u0432\\\\u0430\\\\u043d\\\\u044c\\\\n\\\\u0422\\\\u0430\\\\u043d\\\\u0437\\\\u0430\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u0422\\\\u043e\\\\u0433\\\\u043e\\\\n\\\\u0422\\\\u0440\\\\u0438\\\\u043d\\\\u0438\\\\u0434\\\\u0430\\\\u0434 \\\\u0438 \\\\u0422\\\\u043e\\\\u0431\\\\u0430\\\\u0433\\\\u043e\\\\n\\\\u0422\\\\u0443\\\\u0432\\\\u0430\\\\u043b\\\\u0443\\\\n\\\\u0422\\\\u0443\\\\u043d\\\\u0438\\\\u0441\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u043a\\\\u043c\\\\u0435\\\\u043d\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u043a\\\\u0441 \\\\u0438 \\\\u041a\\\\u0435\\\\u0439\\\\u043a\\\\u043e\\\\u0441\\\\n\\\\u0422\\\\u0443\\\\u0440\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0423\\\\u0433\\\\u0430\\\\u043d\\\\u0434\\\\u0430\\\\n\\\\u0423\\\\u0437\\\\u0431\\\\u0435\\\\u043a\\\\u0438\\\\u0441\\\\u0442\\\\u0430\\\\u043d\\\\n\\\\u0423\\\\u043a\\\\u0440\\\\u0430\\\\u0438\\\\u043d\\\\u0430\\\\n\\\\u0423\\\\u043e\\\\u043b\\\\u043b\\\\u0438\\\\u0441 \\\\u0438 \\\\u0424\\\\u0443\\\\u0442\\\\u0443\\\\u043d\\\\u0430 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0423\\\\u0440\\\\u0443\\\\u0433\\\\u0432\\\\u0430\\\\u0439\\\\n\\\\u0424\\\\u0430\\\\u0440\\\\u0435\\\\u0440\\\\u0441\\\\u043a\\\\u0438\\\\u0435 \\\\u043e\\\\u0441\\\\u0442\\\\u0440\\\\u043e\\\\u0432\\\\u0430\\\\n\\\\u0424\\\\u0438\\\\u0434\\\\u0436\\\\u0438\\\\n\\\\u0424\\\\u0438\\\\u043b\\\\u0438\\\\u043f\\\\u043f\\\\u0438\\\\u043d\\\\u044b\\\\n\\\\u0424\\\\u0438\\\\u043d\\\\u043b\\\\u044f\\\\u043d\\\\u0434\\\\u0438\\\\u044f\\\\n\\\\u0424\\\\u0440\\\\u0430\\\\u043d\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0424\\\\u0440\\\\u0430\\\\u043d\\\\u0446\\\\u0443\\\\u0437\\\\u0441\\\\u043a\\\\u0430\\\\u044f \\\\u041f\\\\u043e\\\\u043b\\\\u0438\\\\u043d\\\\u0435\\\\u0437\\\\u0438\\\\u044f\\\\n\\\\u0425\\\\u043e\\\\u0440\\\\u0432\\\\u0430\\\\u0442\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0430\\\\u0434\\\\n\\\\u0427\\\\u0435\\\\u0440\\\\u043d\\\\u043e\\\\u0433\\\\u043e\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0435\\\\u0445\\\\u0438\\\\u044f\\\\n\\\\u0427\\\\u0438\\\\u043b\\\\u0438\\\\n\\\\u0428\\\\u0432\\\\u0435\\\\u0439\\\\u0446\\\\u0430\\\\u0440\\\\u0438\\\\u044f\\\\n\\\\u0428\\\\u0432\\\\u0435\\\\u0446\\\\u0438\\\\u044f\\\\n\\\\u0428\\\\u0440\\\\u0438-\\\\u041b\\\\u0430\\\\u043d\\\\u043a\\\\u0430\\\\n\\\\u042d\\\\u043a\\\\u0432\\\\u0430\\\\u0434\\\\u043e\\\\u0440\\\\n\\\\u042d\\\\u043a\\\\u0432\\\\u0430\\\\u0442\\\\u043e\\\\u0440\\\\u0438\\\\u0430\\\\u043b\\\\u044c\\\\u043d\\\\u0430\\\\u044f \\\\u0413\\\\u0432\\\\u0438\\\\u043d\\\\u0435\\\\u044f\\\\n\\\\u042d\\\\u0440\\\\u0438\\\\u0442\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u042d\\\\u0441\\\\u0442\\\\u043e\\\\u043d\\\\u0438\\\\u044f\\\\n\\\\u042d\\\\u0444\\\\u0438\\\\u043e\\\\u043f\\\\u0438\\\\u044f\\\\n\\\\u042e\\\\u0410\\\\u0420\\\\n\\\\u042e\\\\u0436\\\\u043d\\\\u0430\\\\u044f \\\\u041a\\\\u043e\\\\u0440\\\\u0435\\\\u044f\\\\n\\\\u042e\\\\u0436\\\\u043d\\\\u0430\\\\u044f \\\\u041e\\\\u0441\\\\u0435\\\\u0442\\\\u0438\\\\u044f\\\\n\\\\u042f\\\\u043c\\\\u0430\\\\u0439\\\\u043a\\\\u0430\\\\n\\\\u042f\\\\u043f\\\\u043e\\\\u043d\\\\u0438\\\\u044f\",\"li_nm\":\"Selectbox\"},{\"lid\":\"1680697019488\",\"ls\":\"60\",\"loff\":\"\",\"li_type\":\"ta\",\"li_ph\":\"Please provide any additional information regarding your clinical or research inquiry.\",\"li_req\":\"y\",\"li_rows\":\"3\",\"li_nm\":\"Textarea\"},{\"lid\":\"1680697037405\",\"ls\":\"70\",\"loff\":\"\",\"li_type\":\"cb\",\"li_req\":\"y\",\"li_label\":\"I consent to the processing of my personal data.\",\"li_checked\":\"y\",\"li_nm\":\"Checkbox\"}]\\nLearn more aboutOncobox\\n![](https://static.tildacdn.com/tild3738-3464-4333-b061-663736366136/3.png)\\nJoin us in pushing the boundaries of clinical and research development. From groundbreaking clinical trials to pioneering biomarker and CDx advancements, we\\'re dedicated to transforming cancer care and improving patient outcomes. Ready to make a difference? Reach out and let\\'s collaborate!\\n[](http://oncobox.com/<#closepopup>)\\nYour inquiry has been submitted. Our team will contact you shortly.\\n[](http://oncobox.com/<#closepopup>)\\n![](https://static.tildacdn.com/tild3065-3139-4230-b365-323236393664/Group_1790.svg)\\n![](https://static.tildacdn.com/tild6563-3061-4839-b864-323966346139/Group_1793.svg)\\n2015\\n2017\\n2018\\n2020\\n2023\\nCompany Inception\\nY Combinator\\nDiagnostic Platform Launch & Key Research Publication\\nUnique Biobank Collection & Clinical Trials Launch\\nClinical Trial Completion & US Patent Acquisition\\nFounded with the mission to revolutionize the field of precision oncology, leveraging cutting-edge system biology and omics technologies.\\nA major milestone for the company, highlighting its pioneering efforts in oncodiagnostics and greatly accelerating its business development.\\nIntroduced a platform that enhances the precision of cancer treatment. A paper in Seminars in Cancer Biology detailed its scientific principles and efficacy.\\nObtained unique gene expression profiles from healthy tissues, partially published in Nature Scientific Data. Initiated a multicentral prospective clinical trial.\\nConcluded a prospective trial with 250 patients, yielding promising results, with publication preparation underway. Additionally, secured a patent from the USPTO.\\n![](https://static.tildacdn.com/tild6532-3432-4337-a363-666330643337/2.png)\\n![](https://static.tildacdn.com/tild3166-3461-4664-b631-396533393731/3.png)\\n![](https://static.tildacdn.com/tild6538-6335-4433-a134-386234343538/4.png)\\n![](https://static.tildacdn.com/tild6232-3333-4265-a137-653431323036/5.png)\\n![](https://static.tildacdn.com/tild3835-3131-4361-a335-356238643238/9.png)\\n![](https://static.tildacdn.com/tild6663-3730-4236-b463-323638356135/8.png)\\n![](https://static.tildacdn.com/tild3261-3830-4930-a130-393461663933/1.png)\\n![](https://static.tildacdn.com/tild3130-3966-4330-b730-346632376661/7.png)\\n![](https://static.tildacdn.com/tild6661-3431-4662-a439-623139633734/6.png)\\nNews\\nOncobox will present the findings of a prospective clinical trial NCT03724097 on the prescription of anticancer drugs using RNA sequencing and the Oncobox platform at the WIN Symposium⟨34⟩, endorsed by ASCO, in Abu Dhabi, UAE, on March 1, 2024.\\nWIN Symposium 2024: Results of Prospective Clinical Study\\nOncobox has been granted a U.S. patent for the advanced genetic information analysis platform! This milestone not only underscores our commitment to innovation in personalized medicine but also sets a new standard in genetic diagnostics using RNA.\\nPioneered a machine learning approach⟨35⟩ to identify gene markers that predict the effectiveness of bortezomib in treating multiple myeloma. This breakthrough, featuring key biomarkers like FGFR3 and MAF, promises more tailored and effective treatments for this widespread cancer in the elderly.\\nOncobox Secures US Patent for Cutting-Edge Genetic Platform\\nOncobox Unveils ML-Powered Breakthrough in Myeloma Therapy\\n15 February 2024\\n20 April 2023\\n06 November 2022\\n![⟨36⟩](http://oncobox.com/<#first>)\\nThe research is supported by grants from Amazon and Microsoft.\\nhello@oncobox.com\\n![](https://static.tildacdn.com/tild3835-6561-4865-b033-393433343635/Group_1628.svg)\\n![](https://static.tildacdn.com/tild6132-3634-4361-a631-316136383963/Group_1629.svg)\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ http://oncobox.com/<#t-main-content>: To main content\\n⟨2⟩ http://oncobox.com/</#01>: Diagnostics\\n⟨3⟩ http://oncobox.com/</#02>: Clinical effectiveness\\n⟨4⟩ http://oncobox.com/</#03>: Research\\n⟨5⟩ http://oncobox.com/</#04>: About\\n⟨6⟩ https://static.tildacdn.com/tild3536-3163-4837-a433-306336613135/oncobox_logo.svg: ![\\n⟨7⟩ https://static.tildacdn.com/tild6238-3435-4762-b232-356638643536/burger.svg: ![\\n⟨8⟩ http://oncobox.com/</login>: Log in\\n⟨9⟩ https://static.tildacdn.com/tild3366-3836-4138-b664-303963636466/Vector_1.svg: ![\\n⟨10⟩ http://oncobox.com/<#01>: Diagnostics\\n⟨11⟩ http://oncobox.com/<#02>: Clinical effectiveness\\n⟨12⟩ http://oncobox.com/<#03>: Research\\n⟨13⟩ http://oncobox.com/<#04>: About\\n⟨14⟩ https://static.tildacdn.com/tild6663-3763-4539-a434-353337623134/Vector_1.svg: ![\\n⟨15⟩ http://oncobox.com/<#test>: Learn more\\n⟨16⟩ https://static.tildacdn.com/tild6539-3737-4833-a466-353932613566/757575.svg: ![\\n⟨17⟩ https://static.tildacdn.com/tild6333-3464-4265-a336-323738343539/Frame_1536.svg: ![\\n⟨18⟩ http://oncobox.com/<https:/www.mdpi.com/2227-9059/8/3/67/htm>: Biomedicines\\n⟨19⟩ https://static.tildacdn.com/tild6165-6638-4763-b062-666135303734/Vector_1.svg: ![\\n⟨20⟩ https://static.tildacdn.com/tild6138-3764-4163-b561-643338613866/34.svg: ![\\n⟨21⟩ https://static.tildacdn.com/tild3266-3261-4631-a264-373732356263/Frame_1535.svg: ![\\n⟨22⟩ http://oncobox.com/<https:/ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0113-x>: Experimental Hematology & Oncology\\n⟨23⟩ https://static.tildacdn.com/tild3239-6433-4966-a239-626532636239/01010.svg: ![\\n⟨24⟩ https://static.tildacdn.com/tild3734-3836-4836-b033-636362326561/Frame_1537.svg: ![\\n⟨25⟩ http://oncobox.com/<https:/molecularcasestudies.cshlp.org/content/5/2/a003434.long>: CSH Molecular Case Studies\\n⟨26⟩ https://static.tildacdn.com/tild6634-6263-4439-b234-613933323062/Frame_1526.svg: ![\\n⟨27⟩ https://static.tildacdn.com/tild6132-3261-4630-b839-373865323636/Frame_1535.svg: ![\\n⟨28⟩ http://oncobox.com/<https:/www.frontiersin.org/articles/10.3389/fonc.2019.01026/full>: Frontiers in Oncology\\n⟨29⟩ http://oncobox.com/</our_research>: View articles\\n⟨30⟩ https://static.tildacdn.com/tild3136-3836-4362-a531-356431396634/Vector_1.svg: ![\\n⟨31⟩ https://static.tildacdn.com/tild3231-3634-4537-a133-336236623039/Group_1594.svg: ![\\n⟨32⟩ https://static.tildacdn.com/tild3964-6561-4834-b039-356634616462/Group_1793.svg: ![\\n⟨33⟩ https://static.tildacdn.com/tild6331-6132-4739-b063-613566653439/Group_1701.svg: ![\\n⟨34⟩ http://oncobox.com/<https:/win-burjeel-symposium.com/>: WIN Symposium\\n⟨35⟩ http://oncobox.com/<https:/www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.652063/full>:  machine learning approach\\n⟨36⟩ https://static.tildacdn.com/tild3533-3866-4733-b835-633931316362/logo_white.svg: ![\\n' fit_markdown='' fit_html=''",
  "generated_description": "## Oncobox: Revolutionizing Cancer Treatment \n\n**Mission**: Oncobox is dedicated to finding the right cancer drug for each patient, leveraging tailor-made solutions for personalizing treatment.\n\n### What They Do:\n\nOncobox started with a clear goal: to address the critical need for a data-driven approach in cancer treatment. Many late-stage cancer patients face the daunting reality of ineffective treatments, often suffering due to the lack of targeted therapy options tailored to their unique genetic makeup. Oncobox's solution? Affordable personalized genetic profiling.\n\n**How It Works**:\n- Oncobox Dx analyzes tumor DNA and RNA, focusing on essential molecular pathways and genetic profiles.\n- This sophisticated analysis helps clinicians identify the most effective targeted therapies from over 150 available on the market.\n- They deliver a clinically actionable report that provides a ranked list of medications likely to benefit specific patients, significantly increasing the effectiveness of treatment.\n\n### Impact:\n\nIn a clinical study involving 900 late-stage cancer patients, Oncobox improved the effectiveness of targeted therapies from a mere 25% to an impressive 64%. This kind of data-driven tool is a game changer, as it helps mitigate the risks of ineffective drug trials.\n\n**Partnerships**: The company actively collaborates with pharmaceutical firms, hospitals, payers, and genomic centers to better integrate their innovative solutions into the healthcare landscape.\n\n### Team and Collaboration:\n\nLocated in Walnut, CA, and part of Y Combinator’s S17 batch, Oncobox boasts a team of 11 skilled employees and a scientific advisory board with experts from prestigious institutions like UCLA and Johns Hopkins University.\n\n### The Bigger Picture:\n\nWhile oncology can often feel like a minefield of trial and error, Oncobox is making strides toward a more precise and efficient approach. By utilizing cutting-edge genomic technologies and machine learning, it’s paving the way for what they call “deep molecular profiling,” moving beyond guesswork and toward a future where cancer care is centered around the individual's molecular data.\n\n### Conclusion:\n\nOncobox is more than just a diagnostics company; it’s a beacon of hope for late-stage cancer patients, offering tailored solutions that could transform their treatment journey. Interested in learning more? Check out their website at [oncobox.com](http://oncobox.com) or reach out via email at hello@oncobox.com. \n\nThe future of oncology is personalized—thanks to the innovative solutions from Oncobox."
}